3.12. Analysis.
Comparison 3 Leukotriene Receptor Antagonists (LTRA) + ICS vs. ICS (TAPERING protocol) in WELL CONTROLLED patients, Outcome 12 Absolute change in mean daily use of B2‐agonists (puffs/week) at lowest tolerated dose (at 6‐24 weeks).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.